Opioids Market Overview to 2023 - Opioids in Western Europe
|出版商||CBR Pharma Insights||商品編碼||318490|
|出版日期||內容資訊||英文 74 Pages
|Opioids(類鴉片物質)市場未來展望:西歐的Opioids(類鴉片物質)市場 Opioids Market Overview to 2023 - Opioids in Western Europe|
|出版日期: 2014年10月31日||內容資訊: 英文 74 Pages||
The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%).
Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes. Amidst concerns regarding inadequate pain management due to low accessibility, there are also concerns regarding a lack of significant clinical evidence of their role in managing chronic pain. However, new abuse-deterrent technologies provide an incentive to prescribe more opioids in pain management by alleviating concerns over misuse potential. The approval of such new drugs and formulations has proved a new impetus to growth in opioid usage in the five major Western European countries.
Opioids are largely used for two medicinal purposes: pain management and substitution treatment for drug dependence. Several of the recently approved and pipeline opioid analgesics have a strong focus on reducing misuse potential, which is one of the most significant barriers to usage in pain management. However, usage is on the rise following the introduction of new abuse-deterrent formulations of fentanyl and oxycodone, and initiatives that aim to rationalize usage in pain management. Demand is also high in substitution treatment. While both methadone and buprenorphine are approved for substitute treatment, buprenorphine usage increased in Europe after the approval of Suboxone in 2006, in combination with naloxone, a pure opioid antagonist that acts as an abuse-deterrent.
The report covers the five major Western European countries (the UK, Germany, France, Italy and Spain) and includes -